Empagliflozin Gets Priority Review for Heart Failure Independent of LVEF
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
The application is supported by data from the phase 3 EMPEROR-Preserved trial.
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
The phase 3 EMPEROR-Preserved trial included 5988 adult patients with heart failure with preserved ejection fraction, with and without diabetes.
Omecamtiv mecarbil is a selective small molecule cardiac myosin activator.
Blocking the endothelin pathway could represent a new mode of action to lower blood pressure in resistant hypertension, according to investigators.
Investigators conducted a meta-analysis of randomized controlled trials on the effect of SGLT-2 inhibitors on patients with HFpEF.
The findings were consistent across key subgroups examined (eg, LVEF<60%, diabetes)
Sotagliflozin is an investigational dual sodium-glucose co-transporter types 1 and 2 (SGLT1, SGLT2) inhibitor.
A study was conducted to determine the relationship between obesity, age at menopause, and heart failure incidence.